abstract |
The present application relates to the treatment of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules, and cancer, both alone and in combination with other therapeutic agents such as immunostimulants such as PD-1 / And their use in combination with inhibitors. |